Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 Feb 15.
Published in final edited form as: Nat Microbiol. 2016 Aug 15;1:16154. doi: 10.1038/nmicrobiol.2016.154

Structure of the essential Haemophilus influenzae UDP-diacylglucosamine pyrophosphohydrolase LpxH in lipid A biosynthesis

Jae Cho 1, Chul-Jin Lee 1,2, Jinshi Zhao 1, Hayley E Young 1, Pei Zhou 1,*
PMCID: PMC5081216  NIHMSID: NIHMS805558  PMID: 27780190

Abstract

In most Gram-negative pathogens, the hydrolysis of UDP-2,3-diacylglucosamine to generate lipid X in lipid A biosynthesis is catalyzed by the membrane-associated enzyme LpxH. We report the crystal structure of LpxH in complex with its product, lipid X, unveiling a unique insertion lid above the conserved architecture of calcineurin-like phosphoesterases. This structure reveals elaborate interactions surrounding lipid X and provides molecular insights into the substrate selectivity, catalysis, and inhibition of LpxH.


The outer leaflet of the outer membrane of Gram-negative bacteria is enriched with lipopolysaccharide (LPS), which is anchored into the membrane through a hexaacylated disaccharide lipid called lipid A1,2. Lipid A serves as a protective barrier to shield bacterial cells from the damage of antibiotics and detergents3 and is the active component of endotoxin that elicits potent host responses to bacterial infection.

The biosynthesis of lipid A in Escherichia coli involves nine constitutive enzymes of the Raetz pathway (Supplementary Fig. 1)1. The first membrane-associated reaction of the pathway, the cleavage of the pyrophosphate group of UDP-2,3-diacylglucosamine (UDP-DAGn) to form lipid X, is carried out by LpxH in β- and γ-proteobacteria4, LpxI in α-proteobacteria5, and LpxG in Chlamydiae6 (Fig. 1a). LpxH and LpxG are unique members of the metal-dependent calcineurin-like phosphoesterase (CLP) family, though they share limited sequence similarity6. LpxI, on the other hand, is structurally and mechanistically unrelated to LpxH and LpxG7,8. LpxI uses water to attack the β-phosphate5,7, whereas LpxH and LpxG use water to attack the α-phosphate on the common UDP-DAGn substrate4,6. Among these three enzymes, LpxH is most widespread, functioning in ~70% of Gram-negative bacteria and the vast majority of Gram-negative pathogens.

Figure 1. Structure of the LpxH-lipid X complex.

Figure 1

a, Cleavage of the pyrophosphate group of UDP-2,3-diacylglucosamine to form lipid X and UMP by LpxH (magenta) and its functional orthologues LpxI and LpxG (orange). b, Ribbon representation of LpxH, with blue to red corresponding with N- to C-terminus. Lipid X is shown as a stick model, and the di-manganese cluster is shown as spheres. The insertion “lid” is boxed. c, Topology diagram of LpxH. The core domain is denoted in green, and the insertion lid is colored in orange. Locations of metal binding residues are denoted as red dots. d, Coordination of the di-manganese cluster in LpxH. The manganese ions are shown as spheres. Sidechains of manganese chelating residues are shown as stick models, and their distances to the manganese ions are labeled in Å. Lipid X is shown as a stick model to illustrate its location in the active site. e, Recognition of the glucosamine-1-phosphate headgroup of lipid X by LpxH. LpxH residues from the core domain are colored in green, and those from the insertion lid are colored in orange. Sidechains of residues that interact with lipid X through polar interactions are shown as stick models. Lipid X, colored in cyan, is also shown as a stick model. Positions of the glucosamine ring are numbered in red. The manganese ions are shown in spheres (with a reduced radius). Side and top views of the LpxH-lipid X complex in the surface representation are shown in panels f and g respectively, illustrating the engulfment of lipid X by LpxH within the hydrophobic chamber. The backbone of LpxH is depicted as the ribbon diagram. Lipid X and its acyl-chain-interacting residues are denoted as stick models. Lipid X is colored in cyan, and the core domain and insertion lid of LpxH are colored in green and orange, respectively. Clustered hydrophobic surface residues in the insertion lid not involved in lipid X interaction are shown as stick models and are colored in yellow, revealing a potential surface area for membrane association. The structure is a representative model derived from the best quality crystal.

As constitutive lipid A biosynthesis is required for bacterial viability and pathogenesis, essential lipid A enzymes, including LpxH9, are attractive targets for the development of novel antibiotics against Gram-negative pathogens. Recently, an LpxH-targeting antibiotic has been reported10, opening the arena for targeted development of LpxH inhibitors. Despite the molecular cloning and biochemical characterization of LpxH over a decade ago4,9, its structure has not yet been elucidated, leaving fundamental questions about this membrane-associated, essential lipid pyrophosphatase unanswered.

In order to provide molecular insights into the catalysis and inhibition of LpxH, we have crystallized Haemophilus influenzae LpxH (HiLpxH) in complex with its product lipid X (Supplementary Table 1). The structure of LpxH (Fig. 1bc) reveals a conserved core architecture shared with the CLP enzymes, such as PP-111. However, there are major distinctions. The core domain of LpxH consists of two tightly packed central β-sheets, instead of three β-sheets in PP-1. These two prominent β-sheets consist of a total of eleven β-strands arranged in a mixed parallel and anti-parallel fashion. Starting with the N-terminus in the middle of β-sheet 1, the backbone forms a β1-α1-β2-α2-β3-α3-β4 scaffold, which then crosses over to β-sheet 2 to form two antiparallel β-strands (β5 and β6). Following this, there exists an elongated, triangle-shaped insertion domain formed by two long helices (α1′ and α3′) connected by a short helix (α2′). This insertion (dubbed the “lid” domain in Fig. 1bc) functions similarly to the lid of the pitfall trap of a pitcher plant to engulf lipid X. Following the insertion domain, there is another helix (α4) that packs against β-sheet 2. The α4 helix is followed by three mixed orientation β-strands (β7, β8 and β9) before the backbone crosses back to β-sheet 1 to form the last two antiparallel β-strands (β10 and β11). The active site of LpxH is located between the insertion lid and the core domain (Fig. 1bc).

Within the catalytic site of LpxH, electron densities of two metal ions can be identified. As LpxH is most active in the presence of Mn2+, and since our previous EPR study has revealed the presence of a di-manganese cluster in LpxH12, these two densities were interpreted as manganese ions. Of the two manganese ions, the first ion (Mn1) is coordinated by sidechains of D42, N80, H115 and H196, while the second ion (Mn2) is coordinated by sidechains of D9, H11, and D42, with D42 bridging the di-manganese cluster (Fig. 1d). The short distances between these residues and the di-manganese cluster are consistent with their suggested role within the signature metal chelating motifs (D9 and H11 of the DXH motif, D42 of the GDXXD motif, N80 of the GNRD motif, H115 of the HXD motif, and H196 of the GHXH motif) of the CLP enzymes (Supplementary Fig. 2). Substitutions of these residues by alanine (D9A, H11A, D42A, H115A, and H196A) dramatically reduced the specific activity of LpxH by 5000- to 200,000-fold12.

As LpxH was crystallized in the absence of any added lipid A intermediates, we were surprised to observe lipid X, the product of LpxH, sandwiched between the core domain and the insertion lid of LpxH, with its glucosamine-1-phosphate headgroup sitting right above the di-manganese cluster within the active site (Fig. 1e). In order to verify that the lipid molecule co-crystallized with LpxH was indeed lipid X, we subjected the crystallization sample to single-phase Bligh-Dyer extraction13 followed by reversed-phase liquid chromatography mass spectrometry (RPLC-MS) analysis. Consistent with the predicted mass for E. coli lipid X ([M-H] m/z of 710.42), a singly charged species with [M-H] at m/z 710.44 was observed as a discrete peak eluting from the column (Supplementary Fig. 3a,b). MS/MS analysis also yielded components consistent with secondary fragmentation of lipid X (Supplementary Fig. 3c), confirming co-purification of lipid X with the overexpressed LpxH and suggesting a high flux of lipid X and UDP-DAGn despite their low steady state levels.

The electron density of lipid X is well defined for the glucosamine-1-phosphate headgroup, the entire 2-N-linked β-hydroxymyristoyl chain, and the first half of the 3-O-linked β-hydroxymyristoyl chain (Supplementary Fig. 4). Electron density for the remaining part of the 3-O-linked acyl chain, albeit weak, is visible at lower contour levels. The glucosamine-1-phosphate adopts a chair conformation, with the 1-phosphate group in the axial configuration and the remaining substituents of the hexose ring in the equatorial configuration. An extensive array of LpxH residues can be identified that interact with every polar group of the glucosamine-1-phosphate headgroup. The 1-phosphate group in particular is very well recognized; it forms two salt bridges with R81 of the GNRD motif, which itself is anchored by D45 from the GDXXD motif of a neighboring loop. Mutation of R81A decreased the specific activity of LpxH by 7,000-fold compared to the wild-type enzyme12, consistent with its critical contribution to the recognition of the substrate. The 1-phosphate group is additionally recognized through hydrogen bonds with the manganese-chelating residue N80 and H198 of the GHXH motif, the latter of which is anchored by a hydrogen bond with D215. In addition to interacting with residues of the core domain, the 1-phosphate group of lipid X also forms a salt bridge with K165 from the α3′ helix of the insertion lid and is engaged in a hydrogen bond with the β-hydroxyl group of its 2-N-linked β-hydroxymyristoyl chain. The nitrogen atom of the 2-N-linked acyl chain is fixed in space by a hydrogen bond with S161 of the α3′ helix from the insertion lid. Recognition of polar groups at the 3- and 4-positions is achieved entirely within the insertion lid. K168 at the end of the α3′ helix forms three hydrogen bonds with the β-hydroxyl group and the carbonyl oxygen of the 3-O-linked β-hydroxymyristoyl chain as well as the 4-hydroxyl group of the glucosamine ring. The carbonyl group of the 3-O-linked acyl chain additionally forms a hydrogen bond with S161, whereas the 4-hydroxyl group is further recognized by D123 of the insertion lid, which also serves as the cap of the insertion helix α1′. The last polar group of the glucosamine ring, the 6-hydroxyl group, forms a hydrogen bond with the manganese-chelating residue H196. With the exception of K165, all of the residues directly interacting with the 1-phosphate group are strictly conserved (Supplementary Fig. 2). As the level of UDP-DAGn only represents 0.005% of the total bacterial phospholipids14, such an elaborate array of specific interactions surrounding the glucosamine-1-phosphate headgroup, a molecular entity shared by lipid X and UDP-DAGn, bestows LpxH with the extraordinary ability to scavenge its substrate UDP-DAGn from an overwhelming amount of competing phospholipids in the bacterial inner membrane.

The two acyl chains of lipid X are recognized differently. The 2-N-linked β-hydroxymyristoyl chain is nearly completely buried within a hydrophobic chamber at the interspace between the core domain and the insertion lid (Fig. 1f). Lining the hydrophobic chamber are conserved residues from the core domain (I48, F83, and L84) and from the insertion lid (F129 and V133 from the α1′ helix, L138 and F142 from the α2′ helix, and I157 from the α3′ helix) that form extensive interactions with the 2-N-linked β-hydroxymyristoyl chain (Fig. 1g). The 3-O-linked β-hydroxymyristoyl chain, however, does not interact with the core domain. It rises rapidly through an open area above the active site, with its remaining acyl chain gliding over the surface of the insertion lid and forming hydrophobic interactions with F129, V133 of the α1′ helix and I157 of the α3′ helix. A significant portion of the 3-O-linked acyl chain is surface exposed and is likely surrounded by detergent molecules. Similarly, the insertion lid is decorated with a large number of surface-exposed hydrophobic residues (W137, L141, L145, V149, and I153) that do not interact with lipid X. These residues likely facilitate the association of the insertion lid of LpxH with detergent micelles in vitro and with the bacterial inner membrane in vivo.

Recognition of lipid X by LpxH is distinct from its functional orthologue, LpxI, which is structurally unrelated to LpxH7. LpxI consists of an N-terminal lipid-binding domain with a central β-sheet decorated with helices on both sides and a C-terminal catalytic domain7. Lipid X recognition by LpxI is achieved by encapsulating both acyl chains of lipid X in the lipid-binding domain, but with limited interactions of the glucosamine-1-phosphate group. Binding of UDP-DAGn by LpxI induces a conformational switch that brings the catalytic domain close to the lipid-binding domain for specific recognition of the substrate and catalysis. Whether binding of UDP-DAGn by LpxH similarly induces a conformational change remains to be established.

Incubation of UDP-DAGn with LpxH in H218O results in cleavage of the pyrophosphate linkage and incorporation of a solvent molecule into UMP (Supplementary Fig. 5)4. HiLpxH is most active at slightly alkaline pH values and exhibits a sharp decrease in its catalytic activity at acidic pH12. Fitting the data to a single-lobed pH curve reveals a general base with a pKa of ~6.6, consistent with the presence of a catalytic histidine residue in the active site12. After excluding active site histidine residues involved in manganese coordination, we propose that H198, which is located at the far side of Mn2, serves as the catalytic general base to mediate a metal ion-activated water molecule for in-line attack of the α-phosphate group of UDP-DAGn to incorporate18O into the UMP moiety (Supplementary Fig. 5).

Lipid A biosynthesis is required for the viability of virtually all Gram-negative bacteria. Nearly all of the inhibitor development efforts thus far have focused on cytosolic lipid A enzymes, such as LpxC1517. However, targeting late-stage lipid A enzymes such as LpxH may be uniquely advantageous, as inhibition of LpxH results in accumulation of toxic lipid intermediates in the bacterial inner membrane9,10, providing an independent mechanism of bacterial killing.

Recently, a small-molecule inhibitor of E. coli LpxH has been reported, and four resistance mutations to the inhibitor—G48D, L84R, F141L, and R149H—in E. coli LpxH have been isolated10. By mapping these residues onto the structure of HiLpxH, we show that all of the corresponding residues in this orthologue, G49, I85, F142 and R150 (Supplementary Fig. 2), are clustered together around the terminus of the 2-N-linked β-hydroxymyristoyl chain of lipid X (Supplementary Fig. 6). Such an observation suggests that the reported LpxH inhibitor likely targets the hydrophobic chamber between the insertion lid and the core domain and competes with the 2-N-linked acyl chain of the substrate UDP-DAGn for LpxH inhibition.

The prevalence of antibiotic resistance in clinically important Gram-negative pathogens demands novel therapeutic options that target previously unexploited enzymes such as LpxH in the lipid A biosynthetic pathway. The structural elucidation of LpxH in complex with its product lipid X provides a first glimpse of the mechanism and inhibition of LpxH catalysis and sets the stage for future lead optimization campaigns based on structural insights.

Methods

Sample preparation and protein crystallization

The expression construct for HiLpxH was described previously12, containing the full-length enzyme followed by a TEV site and a C-terminal His10-tag. BL21(DE3) cells transformed with the HiLpxH expression vector were grown in the LB medium at 37 °C until O.D.600 reached 0.5. The cells were induced with 1 mM IPTG at 30 °C for 5 hrs, harvested by centrifugation, and then kept frozen at −80 °C until purification. The cell pellet from each liter of culture was resuspended in 30 mL of the lysis buffer containing 200 mM NaCl and 20 mM HEPES (pH 8.0). Resuspended cells were lysed with a French Press. Cell debris was removed by low speed centrifugation at 10,000 × g for 40 minutes. HiLpxH was then extracted with n-dodecyl-β-D-maltopyranoside (DDM; 1.5% w/v) for 2 hrs at 4 °C and subjected to high speed centrifugation at 100,000 × g for 1 hr. After centrifugation, the supernatant was purified by the HisPur™ Ni-NTA gravity-flow chromatography (ThermoFisher Scientific) at 4 °C. Approximately 2 mL of the Ni-NTA resin was used per liter of cell culture. After sample loading, the column was washed with 15–20 column volume of buffer containing 200 mM NaCl and 20 mM HEPES (pH 8.0) and 1.8 mM n-decyl-β-D-thiomaltopyranoside (DTM) (2× critical micelle concentration, CMC). HiLpxH was eluted using 10 column volume of buffer that additionally contains 250 mM imidazole. For the crystallization sample, the C-terminal His10 tag was not removed.

The eluted fractions from the Ni-NTA chromatography were combined, concentrated, and further purified through size-exclusion chromatography (HiPrep 26/60 Sephacryl S-200 HR, GE Healthcare) at a flow rate of 1 mL/min in the presence of 200 mM NaCl, 20 mM HEPES pH 8.0 and 1.08 mM DTM (1.2x CMC). Three fractions of 2 mL each with the highest concentrations were pooled and concentrated to 10 mg/mL with an estimated final DTM concentration of 3.6–4.5 mM (4–5 × CMC). The selenomethionine labeled LpxH sample was prepared using the SelenoMet™ Medium (Molecular Dimensions).

LpxH crystals were obtained by mixing freshly prepared protein solution with mother liquor and additives at a drop ratio of 1:1. The optimal crystallization condition contains 5 mg/mL LpxH in 100 mM NaCl, 10 mM HEPES, 35 mM sodium acetate pH 4.1, 2.2% PEG 4000, 0.3 mM sulfonyl piperazine, 0.7% DMSO, 22% glycerol, and ~3–4 mM DTM. Crystals started to appear after 7–10 days at 15 °C. Suitable-sized crystals were cryoprotected using the corresponding crystallization buffer containing 40% glycerol before flash-freezing for data collection.

Data collection and structural analysis

Diffraction data were collected at the Northeastern Collaborative Access Team (NECAT) beamlines (24-ID-C and 24-ID-E). The selenium single anomalous dispersion (Se-SAD) dataset was obtained by merging diffraction data from two crystals collected at the wavelength of the selenium absorption peak (0.97912 Å). The native dataset was collected at the wavelength of 1.0000 Å. The diffraction data were processed using XDS and AIMLESS modules in the CCP4 suite and were truncated and scaled with the University of California, Los Angeles anisotropy diffraction server18,19. Identification of heavy-atom sites, Se-SAD phasing, and initial model building were done using AutoSol and AutoBuild modules within the PHENIX suite20. All four predicted Se heavy atom sites were unambiguously identified. The resulting structure was used as the search model for molecular replacement against the native dataset. Restraints of lipid X were generated using the eLBOW module within the PHENIX suite20 and edited manually. Iterative model building and refinement was carried out using COOT21 and PHENIX20. The 2mFo-DFc omit map was generated using PHENIX20. The coordinate of the LpxH-lipid X complex has been deposited to the Protein Data Bank (PDB) with the accession code of 5K8K.

Lipid extraction and mass spectrometry

LpxH-bound lipids were extracted using the single-phase Bligh-Dyer method13 by adding chloroform and methanol to the aqueous solution at a ratio of 1:2:0.8 (v/v). The supernatant of the mixture was dried and re-suspended in methanol and submitted to reversed-phase liquid chromatography electron spray ionization mass spectrometry (RPLC-ESI/MS) analysis using a Shimadzu LC system (comprising of a solvent degasser, two LC-10A pumps and a SCL-10A system controller) coupled to a TripleTOF5600 mass spectrometer (Sciex, Framingham, MA). LC was operated at a flow rate of 200 μL/min with the following linear gradients: 100% of mobile phase A was held isocratically for 2 min and then linearly increased to 100% mobile phase B over 3 min and held at 100% B for 2.5 min. At the end, the gradient was returned to 100% mobile phase A and held for 2 min. Mobile phase A consisted of methanol/acetonitrile/aqueous 1 mM ammonium acetate (60/20/20, v/v/v). Mobile phase B consisted of 100% ethanol containing 1 mM ammonium acetate. A Zorbax SB-C8 reversed-phase column (5 μm, 2.1 × 50 mm) was obtained from Agilent (Palo Alto, CA). The LC eluent was introduced into the ESI source of the mass spectrometer. Instrument settings for the negative ion ESI/MS and MS/MS analysis of lipid species were as follows: Ion spray voltage (IS) = −4500 V; Curtain gas (CUR) = 20 psi; Ion source gas 1 (GS1) = 20 psi; De-clustering potential (DP) = −55 V; Focusing potential (FP) = −150 V. Data acquisition and analysis were performed using the Analyst TF1.5 software (Sciex, Framingham, MA).

Supplementary Material

1

Acknowledgments

This work was supported by grants from the National Institute of General Medical Sciences awarded to P.Z. (GM115355 and GM51310). Diffraction data were collected at the Northeastern Collaborative Access Team beamlines (24-ID-C and 24-ID-E) funded by NIGMS (GM103403). The Pilatus 6M detector on 24-ID-C beam line is funded by a NIH-ORIP HEI grant (RR029205). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. We thank Dr. Ziqiang Guan for assistance with the mass spectrometry analysis and Dr. Brian Coggins for critical reading of this manuscript.

Footnotes

Author contributions

P.Z. conceptualized the study. J.C. and H.E.Y. purified and crystallized LpxH. J.C., C-J. L., and P.Z. determined the structure. J.Z. carried out the mass spectrometry analysis. P.Z. wrote the manuscript with critical inputs from all authors.

Competing interests

The authors declare no competing financial interests.

References

  • 1.Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635–700. doi: 10.1146/annurev.biochem.71.110601.135414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Whitfield C, Trent MS. Biosynthesis and export of bacterial lipopolysaccharides. Annu Rev Biochem. 2014;83:99–128. doi: 10.1146/annurev-biochem-060713-035600. [DOI] [PubMed] [Google Scholar]
  • 3.Needham BD, Trent MS. Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis. Nat Rev Microbiol. 2013;11:467–81. doi: 10.1038/nrmicro3047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Babinski KJ, Ribeiro AA, Raetz CR. The Escherichia coli gene encoding the UDP-2,3-diacylglucosamine pyrophosphatase of lipid A biosynthesis. J Biol Chem. 2002;277:25937–46. doi: 10.1074/jbc.M204067200. [DOI] [PubMed] [Google Scholar]
  • 5.Metzger LEt, Raetz CR. An alternative route for UDP-diacylglucosamine hydrolysis in bacterial lipid A biosynthesis. Biochemistry. 2010;49:6715–26. doi: 10.1021/bi1008744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Young HE, et al. Discovery of the Elusive UDP-Diacylglucosamine Hydrolase in the Lipid A Biosynthetic Pathway in Chlamydia trachomatis. MBio. 2016;7 doi: 10.1128/mBio.00090-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Metzger LEt, Lee JK, Finer-Moore JS, Raetz CR, Stroud RM. LpxI structures reveal how a lipid A precursor is synthesized. Nat Struct Mol Biol. 2012;19:1132–8. doi: 10.1038/nsmb.2393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Metzger LEt, Raetz CR. Purification and characterization of the lipid A disaccharide synthase (LpxB) from Escherichia coli, a peripheral membrane protein. Biochemistry. 2009;48:11559–71. doi: 10.1021/bi901750f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Babinski KJ, Kanjilal SJ, Raetz CR. Accumulation of the lipid A precursor UDP-2,3-diacylglucosamine in an Escherichia coli mutant lacking the lpxH gene. J Biol Chem. 2002;277:25947–56. doi: 10.1074/jbc.M204068200. [DOI] [PubMed] [Google Scholar]
  • 10.Nayar AS, et al. Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay. J Bacteriol. 2015;197:1726–34. doi: 10.1128/JB.02552-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Goldberg J, et al. Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature. 1995;376:745–53. doi: 10.1038/376745a0. [DOI] [PubMed] [Google Scholar]
  • 12.Young HE, Donohue MP, Smirnova TI, Smirnov AI, Zhou P. The UDP-diacylglucosamine pyrophosphohydrolase LpxH in lipid A biosynthesis utilizes Mn2+ cluster for catalysis. J Biol Chem. 2013;288:26987–7001. doi: 10.1074/jbc.M113.497636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–7. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  • 14.Bulawa CE, Raetz CR. The biosynthesis of gram-negative endotoxin. Identification and function of UDP-2,3-diacylglucosamine in Escherichia coli. J Biol Chem. 1984;259:4846–51. [PubMed] [Google Scholar]
  • 15.Barb AW, Zhou P. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. Curr Pharm Biotechnol. 2008;9:9–15. doi: 10.2174/138920108783497668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lee CJ, et al. Drug design from the cryptic inhibitor envelope. Nat Commun. 2016;7:10638. doi: 10.1038/ncomms10638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Erwin AL. Antibacterial drug discovery targeting the lipopolysaccharide biosynthetic enzyme LpxC. In: Silver LL, Bush K, editors. Cold Spring Harb Perspect Med. 2016. pp. 1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Collaborative Computational Project, N. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994;50:760–3. doi: 10.1107/S0907444994003112. [DOI] [PubMed] [Google Scholar]
  • 19.Strong M, et al. Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2006;103:8060–5. doi: 10.1073/pnas.0602606103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213–21. doi: 10.1107/S0907444909052925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–2132. doi: 10.1107/S0907444904019158. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES